Toronto Stocks Edge Lower; Argonaut Gold Slides on C$80 Million Fundraiser
By Adriano Marchese
Toronto-listed shares were mildly lower Monday at midday. Investors are awaiting Wednesday's Bank of Canada decision on interest rates, with many analysts expecting the central bank to stand pat on any hikes or cuts.
In the session, materials, energy and tech were the main laggards, offsetting gains primarily in health tech, consumer services, process industries.
Canada's S&P/TSX Composite Index was 0.20% lower at 20411.42. The blue-chip S&P/TSX 60 fell by 0.09% to 1230.33.
Argonaut Gold shares fell by 11% to 38 Canadian cents (28 cents) after the miner said it plans to raise C$80 million by way of a bought-deal public offering. It plans to use the new money to advance its Magino mine in Ontario and Florida Canyon in Nevada.
Other market movers:
Brookfield Asset Management will evaluate its next steps after its consortium's $11 billion bid for Australia-based Origin Energy was rejected by shareholders. Shares trading in Toronto were down 1.4% at C$47.95.
GoldMining shares were 8% higher at C$1.35 after the company said it has plans to advance a uranium project in the Athabasca Region of Alberta to take advantage of the elevated price of uranium.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
December 04, 2023 12:22 ET (17:22 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks